BRPI0912582A2 - Método de tratar câncer utilizando um inibidor cmet e axl e um inibidor erbb - Google Patents

Método de tratar câncer utilizando um inibidor cmet e axl e um inibidor erbb

Info

Publication number
BRPI0912582A2
BRPI0912582A2 BRPI0912582-5A BRPI0912582A BRPI0912582A2 BR PI0912582 A2 BRPI0912582 A2 BR PI0912582A2 BR PI0912582 A BRPI0912582 A BR PI0912582A BR PI0912582 A2 BRPI0912582 A2 BR PI0912582A2
Authority
BR
Brazil
Prior art keywords
inhibitor
cmet
treating cancer
erbb
axl
Prior art date
Application number
BRPI0912582-5A
Other languages
English (en)
Inventor
Tona M Gilmer
James G Greger
Li Liu
Hong Shi
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912582(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0912582A2 publication Critical patent/BRPI0912582A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0912582-5A 2008-05-05 2009-05-05 Método de tratar câncer utilizando um inibidor cmet e axl e um inibidor erbb BRPI0912582A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05
PCT/US2009/042768 WO2009137429A1 (en) 2008-05-05 2009-05-05 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor

Publications (1)

Publication Number Publication Date
BRPI0912582A2 true BRPI0912582A2 (pt) 2015-07-28

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912582-5A BRPI0912582A2 (pt) 2008-05-05 2009-05-05 Método de tratar câncer utilizando um inibidor cmet e axl e um inibidor erbb

Country Status (19)

Country Link
US (3) US20090274693A1 (pt)
EP (1) EP2274304A4 (pt)
JP (1) JP2011519941A (pt)
KR (1) KR20110004462A (pt)
CN (1) CN102083824A (pt)
AR (1) AR071631A1 (pt)
AU (1) AU2009244453B2 (pt)
BR (1) BRPI0912582A2 (pt)
CA (1) CA2723699A1 (pt)
CL (1) CL2009001063A1 (pt)
EA (1) EA020779B1 (pt)
IL (1) IL209057A0 (pt)
MX (1) MX2010012101A (pt)
PE (1) PE20091832A1 (pt)
SG (1) SG190623A1 (pt)
TW (1) TW201006829A (pt)
UY (1) UY31800A (pt)
WO (1) WO2009137429A1 (pt)
ZA (1) ZA201007722B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
HUE061117T2 (hu) 2009-03-25 2023-05-28 Genentech Inc Anti-FGFR3 antitestek és eljárások alkalmazásukra
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
AR077595A1 (es) * 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SI3351558T1 (sl) * 2009-11-13 2020-07-31 Daiichi Sankyo Europe Gmbh Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 Ｃ-ｍｅｔ調節劑醫藥組合物
DK2606070T3 (en) 2010-08-20 2017-03-27 Novartis Ag Antibodies for the epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
EP2656077A1 (en) * 2010-12-23 2013-10-30 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
KR20230158644A (ko) 2011-02-10 2023-11-20 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
US20140179736A1 (en) * 2011-05-02 2014-06-26 Exelixis, Inc. Method of Treating Cancer and Bone Cancer Pain
WO2013043840A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
JP6208140B2 (ja) 2011-10-20 2017-10-04 エクセリクシス， インク． キノリン誘導体の調製プロセス
PL2780338T3 (pl) 2011-11-14 2017-04-28 Ignyta, Inc. Pochodne uracylu jako inhibitory kinaz AXL i c-MET
ES2758433T3 (es) * 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
MY165215A (en) 2012-01-31 2018-03-09 Daiichi Sankyo Co Ltd Pyridone derivatives
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
EP2970126B1 (en) 2013-03-15 2019-03-06 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN105899226B (zh) * 2013-10-14 2020-05-12 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子
KR102322338B1 (ko) * 2014-02-04 2021-11-05 아스텔라스세이야쿠 가부시키가이샤 디아미노헤테로환 카르복스아미드 화합물을 유효 성분으로 하는 의약 조성물
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
EP3125935B1 (en) 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CN106573042A (zh) 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 治疗多发性骨髓瘤的药物组合
EP3239147B9 (en) 2014-12-25 2020-01-08 Ono Pharmaceutical Co., Ltd. Quinoline derivative
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
MX2018016185A (es) 2016-06-21 2019-03-28 Janssen Biotech Inc Moléculas de unión al dominio de fibronectina tipo iii diseñadas de cisteína.
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554562A4 (en) 2016-12-14 2020-11-04 Janssen Biotech, Inc. DOMAINS OF TYPE III FIBRONECTIN BINDING TO CD8A
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
US10836747B2 (en) 2017-01-26 2020-11-17 Ono Pharmaceutical Co., Ltd. Ethane-sulfonate salt of quinoline derivative
CA3053739C (en) 2017-02-15 2023-02-14 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１結合フィブロネクチンｉｉｉ型ドメイン
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
AU2022258566A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
SI2392564T1 (sl) * 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CA2633211A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
US20070213319A1 (en) * 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
CA2671982C (en) * 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
EP2851091B1 (en) * 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
ES2541051T3 (es) * 2007-05-17 2015-07-15 Genentech, Inc. Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US9745278B2 (en) * 2007-09-10 2017-08-29 Boston Biomedical, Inc. Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors

Also Published As

Publication number Publication date
EP2274304A4 (en) 2012-05-30
AR071631A1 (es) 2010-06-30
EA201071268A1 (ru) 2011-06-30
US20090274693A1 (en) 2009-11-05
MX2010012101A (es) 2010-11-30
ZA201007722B (en) 2011-08-31
SG190623A1 (en) 2013-06-28
CN102083824A (zh) 2011-06-01
JP2011519941A (ja) 2011-07-14
AU2009244453B2 (en) 2012-07-19
TW201006829A (en) 2010-02-16
US20130150363A1 (en) 2013-06-13
US20130142790A1 (en) 2013-06-06
AU2009244453A1 (en) 2009-11-12
EA020779B1 (ru) 2015-01-30
IL209057A0 (en) 2011-01-31
CL2009001063A1 (es) 2010-09-24
PE20091832A1 (es) 2009-12-25
CA2723699A1 (en) 2009-11-12
KR20110004462A (ko) 2011-01-13
EP2274304A1 (en) 2011-01-19
UY31800A (es) 2009-11-10
WO2009137429A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
BRPI0912582A2 (pt) Método de tratar câncer utilizando um inibidor cmet e axl e um inibidor erbb
BRPI0909367A2 (pt) calçado e método de fabricação do mesmo
IL195768A0 (en) Method of treating diseases with parp inhibitors
EP2358463A4 (en) INDIRECT AND DIRECT METHOD FOR THE SEQUESTRATION OF POLLUTANTS
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
HK1198243A1 (en) METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH
EP2417127A4 (en) KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH THE SAME
GB0607143D0 (en) Method of locating features of an object
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
HK1151796A1 (en) Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
EP2350641A4 (en) Methods of Treatment
EP2335949A4 (en) TIRE DESIGN METHOD, AND TIRE THUS OBTAINED
EP2335950A4 (en) TIRE DESIGN METHOD, AND TIRE THUS OBTAINED
EP2284144A4 (en) POLYFLUORO-1-ALKANE AND METHOD FOR PRODUCING THE SAME
EP2288908A4 (en) DETECTION OF CHEMICAL TRACE ELEMENTS AND METHOD THEREFOR
ZA201201110B (en) Method of treating cancer
EP2348858A4 (en) PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA
EP2367544A4 (en) METHOD FOR TREATING AGGRESSION
EP2249863A4 (en) METHOD OF ENHANCING WOUND HEALING
IT1391443B1 (it) Gassificatore e metodo di accensione di detto gassificatore
BRPI0910199A2 (pt) método de clareamente da pele
BRPI0925302A2 (pt) método para estimular a biodecomposição e a desgaseificação de locais de descarte de despejos
DK2179056T3 (da) Egfr-inhibitor-behandlingsmarkør

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.